NCT07045155 - Pegmolesatide Treatment for Anemia in Patients Undergoing Long-term Dialysis | Biotech Hunter

Enrollment

240

Participants

Timeline

Start Date

August 1, 2025

Primary Completion Date

December 30, 2027

Study Completion Date

December 30, 2028

Conditions

Dialysis; ComplicationsChronic Kidney Disease 5DRenal Anemia of Chronic Kidney DiseaseRenal AnaemiaRenal Anemia, Chronic

Interventions

DRUG

The rHuEPO Monotherapy Group (Control Group)

The rHuEPO Monotherapy Group (Control Group) will be treated with rHuEPO for the first 16 weeks and then switch to Pegmolesatide treatment for the subsequent 8 weeks.

DRUG

The Pegmolesatide and Roxadustat Combination Therapy Group (Exploratory Group)

The Pegmolesatide and Roxadustat Combination Therapy Group (Exploratory Group) will receive a combination of Pegmolesatide and roxadustat throughout the entire 24-week treatment period.

DRUG

The Pegmolesatide Monotherapy Group (Experimental group)

The Pegmolesatide Monotherapy Group (Experimental Group) will receive Pegmolesatide treatment throughout the entire 24-week period.

Trial Locations (1)

100000

RECRUITING

Chinese PLA General Hospital, Beijing